Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
COVID-19 Vaccination in Primary Immune Deficiencies
2021-000515-24Phase 4Active
- Sponsor
- Erasmus MC
- Start
- Feb 2021
- Modality
- Vaccines & Immunotherapeutics, mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of elasomeran in coronavirus disease 2019 (COVID-19), sponsored by Erasmus MC. Primary endpoint: Antibody response at day 28 after vaccination. Started Feb 2021; status: active.
02
Drugs
elasomeran
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on 2021-000515-24.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-000515-24.